BayPine Acquires Clinical Trial Network CenExel, Plans Digital Infrastructure and AI Expansion

CenExel Clinical Research, a U.S. site network specializing in complex therapeutic areas such as central nervous system (CNS) disorders, will be acquired by BayPine, a private investment firm focused on digital transformation.

Under the agreement, BayPine will become the majority shareholder, with existing investor Webster Equity Partners retaining a minority stake alongside company leadership. Financial terms were not disclosed; the deal is expected to close in the second quarter of 2025, subject to regulatory approval.

CenExel operates 18 sites across major U.S. metro areas and has reportedly supported over 10,000 clinical trials involving more than 100,000 patients. The company provides services across protocol development, patient recruitment and retention, site operations, and data collection. Its infrastructure and therapeutic expertise position it as a partner of interest for biopharma sponsors pursuing functional outsourcing models in clinical research.

CenExel incorporates a mix of digital tools and data-driven methods to support clinical trial execution, particularly in complex therapeutic areas. The company has developed a patient recruitment mobile application to facilitate enrollment and improve match rates based on health profiles and geography. It also uses biomarkers and pharmacodynamic endpoints in early-phase studies to guide trial design and dosing strategies. Through its Clinical Sciences division, CenExel provides input on protocol development and recruitment, emphasizing scientific rigor. The company also participates in initiatives like the Decentralized Trials & Research Alliance to explore models for more flexible and accessible clinical research.

BayPine stated that CenExel is well-suited for expansion through enhanced data infrastructure and AI-based tools aimed at improving trial execution and site performance. According to CenExel CEO Ryan Brooks, the new ownership structure will enable the company to scale its operations and invest in digital capabilities.

CenExel employs over 1,200 people, according to company disclosures, and promotes an integrated model centered on scientific oversight and regulatory compliance. BayPine’s investment is expected to accelerate the company's development into a digitally enabled platform for clinical research.

Photo: zlikovec

Topics: Startups & Deals